Ovarian cancer drug combo trial halted early – what we know
Disease control
Terminated
This study tested a new drug combination (SON-1010 plus atezolizumab) in people with advanced solid tumors, especially platinum-resistant ovarian cancer. The goal was to see if the combination was safe and could slow tumor growth. The trial was terminated early, so results are li…
Phase: PHASE1, PHASE2 • Sponsor: Sonnet BioTherapeutics • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC